Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04621461 · ClinicalTrials.gov registry record · Phase 4
Placebo Controlled Trial to Evaluate Zinc for the Treatment of COVID-19 in the Outpatient Setting
A Phase 4 study of Corona Virus Infection, sponsored by St. Francis Hospital, New York.
- Completed
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT04621461: Completed Phase 4 study of Corona Virus Infection, sponsored by St. Francis Hospital, New York.
NCT04621461 is a Phase 4 study of Corona Virus Infection that has completed, run by St. Francis Hospital, New York. The registered enrollment target is 3 participants, below the 586-participant average among 28 other Corona Virus Infection trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04621461, a Phase 4 study of Corona Virus Infection, has completed, sponsored by St. Francis Hospital, New York.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, double-blind, placebo-controlled trial to assess the efficacy of zinc in a higher risk COVID-19 positive outpatient population.
Primary Outcome
COVID-19 related complications that require the participant to be hospitalized or have an emergency room visit
Conditions Studied
Interventions
- DRUG Placebo
- DIETARY_SUPPLEMENT Zinc Sulfate 220 MG
Study Locations (1)
New York
- St. Francis Hospital - The Heart Center - Roslyn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-12-20 |
| Est. Completion | 2021-02-08 |
| Phase | Phase 4 |
What the finished NCT04621461 record still lists
NCT04621461 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 586-participant average among 28 other Corona Virus Infection trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Corona Virus Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04621461 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04621461 about?
NCT04621461 is a clinical study titled "Placebo Controlled Trial to Evaluate Zinc for the Treatment of COVID-19 in the Outpatient Setting". This is a randomized, double-blind, placebo-controlled trial to assess the efficacy of zinc in a higher risk COVID-19 positive outpatient population.
What is the current status of trial NCT04621461?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2020-12-20. Estimated completion is 2021-02-08.
What conditions does trial NCT04621461 study?
This clinical trial studies the following conditions: Corona Virus Infection.
What interventions are being tested in trial NCT04621461?
The interventions under investigation include: Placebo (DRUG), Zinc Sulfate 220 MG (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04621461?
This trial is sponsored by St. Francis Hospital, New York, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04621461 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Corona Virus Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04621461's enrollment target sits among peer trials
3 29th of 28 the lowest of 28 other Corona Virus Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Corona Virus Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction
COMPLETED · Phase 4
-
Understanding Immunity to the Flu Vaccine in COVID-19 Patients
RECRUITING
-
Risk Factors, Clinical Characteristics and Outcomes of Acute Infection With Coronavirus 2019 (COVID-19) In Children
RECRUITING
-
Determinants of SARS (Severe Acute Respiratory Syndrome)-COV2 (COVID-19) Persistence After Convalescence
RECRUITING
-
A Study to Explore the Role of Gut Flora in COVID-19 Infection
RECRUITING
-
KIDney Injury in Times of COVID-19 (KIDCOV)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI